Phase 3Completed
Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
- Sponsor
- BioQ Pharma, Inc. (Industry)
- Enrollment
- 132 enrolled
- Conditions
- Pain, Postoperative
- Interventions
- Ropivacaine; Placebos
- Ages
- children, adults, older adults
- Registry
- NCT02959476
Full record on ClinicalTrials.gov
From the registry
This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.
Primary outcomes
- Cumulative analgesic effect
History
Last registry update
Primary completion
Started
Registered